Sign in to view content

Avacincaptad Pegol, A Novel C5 Inhibitor, Demonstrates Continued Reduction in Geographic Atrophy Growth: 18-Month Results From GATHER1 Clinical Trial

Jason Hsu, MD

Video
Published 2021

Related

GATHER2 Phase 3 Efficacy Results and GATHER2 Phase 3 Safety Results
Jeffrey S. Heier, MD
Arshad M. Khanani, MD, MA, FASRS
Updates from the Field
2022
Short-term Oral Mifepristone for the Treatment of Central Serous Chorioretinopathy (STOMP-CSC): A Placebo-Controlled Clinical Trial
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2018
20+ Years of The DRCR Network: What We Have Learned About Diabetic Retinopathy
John W. Kitchens, MD
Updates from the Field
2025

Category: AMD-Non-Neovascular

See more